

| | |
|---|---|
| | <p>Dal 1 maggio 2009, ha ricoperto l'incarico dirigenziale triennale di base "Programmazione e coordinamento sperimentazioni di fase III" (U.O.C. Sperimentazioni Cliniche), presso l'Istituto Nazionale per lo Studio e la Cura dei Tumori – Fondazione G.Pascale IRCCS, Napoli.</p> <p>Dal 1 Dicembre 2012 al 31 ottobre 2014, ricopre l'incarico triennale di Alta Specializzazione "Progettazione di studi di fase 0/1" (S.C. Sperimentazioni Cliniche, Dipartimento della Ricerca) presso l'Istituto Nazionale per lo Studio e la Cura dei Tumori – Fondazione G.Pascale IRCCS, Napoli</p> <p>Dal 1 novembre 2014 ad oggi, ricopre l'incarico di professore di seconda fascia di Oncologia Medica, presso il Dipartimento di Oncologia dell'Università di Torino</p> <p>Dal 1 novembre 2014 al 29 febbraio 2016, in servizio come dirigente medico presso la SCU Oncologia Medica dell'A.O.U. San Luigi Gonzaga di Orbassano (TO).</p> <p>Dal 1 marzo 2016 ad oggi, ricopre l'incarico di Direttore della SCU Oncologia presso l'Azienda Ospedaliera Ordine Mauriziano di Torino</p> |
| <p>Incarichi di insegnamento</p> | <p>Dall'anno accademico 2010-2011 all'anno accademico 2012-2013, titolare dell'insegnamento "<i>Ricerca Operativa in Nursing. Statistica per la ricerca sperimentale e tecnologica</i>" nel Corso di Laurea Infermieristica della Seconda Università degli Studi di Napoli (Terzo anno, Secondo semestre).</p> <p>Le lezioni e gli esami del suddetto Corso di Laurea sono state svolte presso l'Istituto Nazionale Tumori – Fondazione "G.Pascale" IRCCS di Napoli.</p> <p>Dal 1 novembre 2014 ad oggi, ricopre l'incarico di professore di seconda fascia di Oncologia Medica, presso il Dipartimento di Oncologia dell'Università di Torino.</p> <p>Anno accademico 2014-2015: Titolare del corso di insegnamento in "Rapporti tra gli aspetti medici e psicologici nei problemi di cura delle malattie oncologiche", Scuola di Specializzazione in Psicologia della Salute</p> <p>Anno accademico 2015-2016 e 2016-2017:</p> <ul style="list-style-type: none"> • Titolare del modulo didattico in "Oncologia" nell'ambito del corso integrato "Medicina Interna I", Corso di Laurea Magistrale in Medicina e Chirurgia, Torino (canale B) • Titolare del modulo didattico in "Oncologia" nell'ambito del corso di insegnamento in "Scienze mediche applicate", del corso di laurea in Tecniche di Radiologia Medica per Immagini e Radioterapia, Sede di Cuneo • Titolare del modulo didattico in "Oncologia medica e cure palliative", nell'ambito del corso di insegnamento "Problemi di salute oncologici", Corso di Studi in Infermieristica, Sede di Torino 2 • Titolare del modulo didattico in "Oncologia medica e cure palliative", nell'ambito del corso di insegnamento "L'infermieristica clinica in area medica", Corso di Studi in Infermieristica, Sede di Cuneo |
| <p>Iscrizione ad associazioni scientifiche e incarichi ricoperti</p> | <p>Socio dell'Associazione Italiana di Oncologia Medica (AIOM). Full member dell'European Society of Medical Oncology (ESMO). Socio dell'International Association for Study of Lung Cancer (IASLC).</p> <p>Da ottobre 2007 a ottobre 2009, eletto componente del Working Group nazionale "AIOM Giovani" dell'Associazione Italiana di Oncologia Medica (mandato 2007-2009).</p> <p>Da ottobre 2009 ad ottobre 2013, eletto componente e nominato Coordinatore Nazionale del Working Group "AIOM Giovani"</p> |

| | |
|--|---|
| | <p>dell'Associazione Italiana di Oncologia Medica (mandato 2009-2011 e mandato 2011-2013).</p> <p>Da ottobre 2013 ad oggi, eletto consigliere nazionale, il prof. Di Maio è membro del Consiglio Direttivo dell'Associazione Italiana di Oncologia Medica (primo mandato: da ottobre 2013 ad ottobre 2015; secondo mandato: da ottobre 2015, in carica fino ad ottobre 2017).</p> <p>Dal 2012 al 2015, ha ricoperto l'incarico di Segretario scientifico delle Linee guida AIOM Neoplasie polmonari.</p> <p>Dal 2015, è componente dell'Ufficio "Comunicazione, Sito, Sperimentazioni, Rapporti con il volontariato, Media, AIOM News, Network" dell'Associazione Italiana di Oncologia Medica.</p> |
| Attività di disegno, conduzione e analisi di sperimentazioni cliniche. Partecipazione a sperimentazioni cliniche | <p>Il prof. Di Maio, dal 2000, ha collaborato all'attività di disegno, conduzione e analisi di numerosi studi clinici, con particolare interesse nell'ambito del tumore del polmone, dell'epatocarcinoma, del tumore del pancreas, dei tumori ginecologici e del tumore della mammella.</p> <p>Il prof. Di Maio ha inoltre partecipato, in qualità di <i>investigator</i>, a numerosi studi clinici condotti nel rispetto delle norme di Good Clinical Practice.</p> |
| Capacità linguistiche | Buona conoscenza della lingua inglese scritta e parlata. |
| Capacità nell'uso delle tecnologie | Buona conoscenza di Microsoft Word, Microsoft Excel, Microsoft Access, S-Plus. |
| Partecipazione a congressi in qualità di relatore | <p>Il prof. Di Maio ha partecipato, in qualità di <i>invited speaker</i> o presentatore di dati originali selezionati per la comunicazione orale, a oltre 200 congressi nazionali e internazionali. Tra le più importanti presentazioni orali, in particolare:</p> <ul style="list-style-type: none"> • Presentazione orale in sessione plenaria al congresso nazionale 2004 dell'Associazione Italiana di Oncologia Medica; • <i>Oral presentation</i> al meeting 2009 dell'American Society of Clinical Oncology; • <i>Oral presentation</i> al meeting 2014 dell'European Society of Medical Oncology. |
| Pubblicazioni su riviste internazionali | <p>Il prof. Di Maio è autore di oltre 180 pubblicazioni su riviste internazionali <i>peer-reviewed</i>, ed è primo o ultimo autore di numerose pubblicazioni su riviste ad elevato <i>impact factor</i>.</p> <p>Tra i principali argomenti di ricerca, il tumore del polmone, l'epatocarcinoma, il tumore del pancreas, le neoplasie ginecologiche e la metodologia della sperimentazione clinica, con particolare interesse per le revisioni sistematiche della letteratura e le metanalisi per dati individuali.</p> <p>L'H-index, aggiornato a novembre 2016, è:</p> <ul style="list-style-type: none"> • 28 (fonte: Web of Science Citation Report) • 31 (fonte: Scopus). |
| <p>191 Bonotto M, Gerratana L, Di Maio M, De Angelis C, Cinausero M, Moroso S, Milano M, Stanzione B, Gargiulo P, Iacono D, Minisini AM, Mansutti M, Fasola G, De Placido S, Arpino G, Puglisi F. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. <i>Breast</i>. 2016 Nov 9;31:114-120. doi:10.1016/j.breast.2016.10.021. [Epub ahead of print] PubMed PMID: 27837704.</p> <p>190 Perrone F, Di Maio M, Del Mastro L. A Case Where Switching the End Points for Clinical Trial Interpretation Might Be the Right Choice. <i>JAMA Oncol</i>. 2016 Nov 10. doi: 10.1001/jamaoncol.2016.4896. [Epub ahead of print] PubMed PMID: 27832249.</p> <p>189 Tampellini M, Benedetto S, Rubatto E, Baratelli C, Di Scipio F, Pirro E, Brizzi MP, Sonetto C, Di Maio M, Berta GN, Scagliotti GV. Bioequivalence of Branded and Generic Oxaliplatin: From Preclinical Assessment to Clinical Incidence of Hypersensitivity Reactions. <i>Anticancer Res</i>. 2016 Oct;36(10):5163-5170. PubMed PMID: 27798876.</p> <p>188 Gori S, Pinto C, Caminiti C, Aprile G, Marchetti P, Perrone F, Di Maio M, Omodeo Salè E, Mancuso A, De Cicco M, Di Costanzo F, Crispino S, Passalacqua R, Merlano M, Zagonel V,</p> | |

Fioretto L, Micallo G, Labianca R, Bordonaro R, Comandone A, Spinsanti S, Iacono C, Nicolis F. Ethics in oncology: principles and responsibilities declared in the Italian Ragusa statement. *Tumori*. 2016 Oct 27;0:doi: 10.5301/tj.5000582. [Epub ahead of print] PubMed PMID: 27791235.

187 Perrone F, Jommi C, Di Maio M, Gimigliano A, Gridelli C, Pignata S, Ciardiello F, Nuzzo F, de Matteis A, Del Mastro L, Bryce J, Daniele G, Morabito A, Piccirillo MC, Rocco G, Guizzaro L, Gallo C. The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. *Ann Oncol*. 2016 Oct 26. pii: mdw433. [Epub ahead of print] PubMed PMID: 27789469.

186 Perrone F., Baldassarre G., Indraco, S., Signoriello, S., Chiappetta, G., Esposito, F., Ferrandina, G., Franco, R., Mezzanzanica, D., Sonego, M., Zulato, E., Zannoni, G., Canzonieri, V., Scambia, G., Sorio, R., Savarese, A., Breda, E., Scollo, P., Ferro, A., Tamberi, S., Febbraro, A., Natale, D., Di Maio, M., Califano, D., Scognamiglio, G., Lorusso, D., Canevari, S., Losito, S., Gallo, C., & Pignata, S. (2016). Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. *Oncotarget*, 5 (2016).

185 Tampellini M, Gned D, Baratelli C, Brizzi MP, Ottone A, Alabiso I, Bertaggia C, Di Maio M, Scagliotti GV, Veltri A. Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy. *Radiol Med*. 2016 Sep 6. [Epub ahead of print] PubMed PMID: 27601143.

184 Ardizzoni A, Tiseo M, Boni L, Di Maio M, Buffoni L, Belvedere O, Grossi F, D'Alessandro V, de Marinis F, Barbera S, Caroti C, Favaretto A, Cortinovis D, Morrica B, Tixi L, Ceschia T, Parisi S, Ricardi U, Grimaldi A, Loregian L, Navarria P, Huber RM, Belani C, Bruswig PF, Scagliotti GV, Sclaro T. Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. *Lung Cancer*. 2016 Oct;100:30-7. doi: 10.1016/j.lungcan.2016.07.026. Epub 2016 Jul 27. PubMed PMID: 27597278.

183 Brizzi MP, Pignataro D, Tampellini M, Scagliotti GV, Di Maio M. Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs? *Expert Rev Anticancer Ther*. 2016 Sep 1:1-10. [Epub ahead of print] PubMed PMID: 27548441.

182 Facchinetti F, Tiseo M, Di Maio M, Graziano P, Bria E, Rossi G, Novello S. Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. *Transl Lung Cancer Res*. 2016 Jun;5(3):301-21. doi: 10.21037/tlcr.2016.06.10. Review. PubMed PMID: 27413712; PubMed Central PMCID: PMC4931127.

181 Bagnoli M, Canevari S, Califano D, Losito S, Di Maio M, Raspagliesi F, Carcangiu ML, Toffoli G, Cecchin E, Sorio R, Canzonieri V, Russo D, Scognamiglio G, Chiappetta G, Baldassarre G, Lorusso D, Scambia G, Zannoni GF, Savarese A, Carosi M, Scollo P, Breda E, Murgia V, Perrone F, Pignata S, De Cecco L, Mezzanzanica D; Multicentre Italian Trials in Ovarian cancer (MITO) translational group. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. *Lancet Oncol*. 2016 Aug;17(8):1137-46. doi: 10.1016/S1470-2045(16)30108-5. Epub 2016 Jul 9. PubMed PMID: 27402147.

180 Moretti A, Ghidini M, De Angelis C, Lambertini M, Cremolini C, Imbimbo M, Berardi R, Di Maio M, Cascinu S, La Verde N. What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research Activities. *PLoS One*. 2016 Jul 12;11(7):e0159146. doi: 10.1371/journal.pone.0159146. eCollection 2016. PubMed PMID: 27403529; PubMed Central PMCID: PMC4942109.

179 Di Maio M, Addeo A. LUX-Lung 7: is there enough data for a final conclusion? *Lancet Oncol*. 2016 Jul;17(7):e266. doi: 10.1016/S1470-2045(16)30116-4. PubMed PMID: 27396642.

178 Di Maio M, Baratelli C, Tampellini M. Measuring the Real Clinical Impact of Randomized Clinical Trials in Oncology: Beyond Citation Counts. *JAMA Oncol*. 2016 Jun 23. doi: 10.1001/jamaoncol.2016.1779. [Epub ahead of print] PubMed PMID: 27355135.

177 Novello S, Pinto C, Torri V, Porcu L, Di Maio M, Tiseo M, Ceresoli G, Magnani C, Silvestri S, Veltri A, Papotti M, Rossi G, Ricardi U, Trodella L, Rea F, Facciolo F, Granieri A, Zagonel V, Scagliotti G. The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations. *Crit Rev Oncol Hematol*. 2016 Aug;104:9-20. doi: 10.1016/j.critrevonc.2016.05.004. Epub 2016 May 13. Review. PubMed PMID: 27286698.

176 Di Maio M, Perrone F. Lessons from clinical trials on quality-of-life assessment in ovarian cancer

trials. *Ann Oncol.* 2016 Jun;27(6):961-2. doi: 10.1093/annonc/mdw153. Epub 2016 Apr 7. PubMed PMID: 27056997.

175 Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzola A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Bria E, Spitaleri G, Rossi A, Novello S. BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR-positive non small cell lung cancer patients: Results from a multicenter Italian observational study. *Lung Cancer.* 2016 May;95:73-81. doi: 10.1016/j.lungcan.2016.02.011. Epub 2016 Feb 26. PubMed PMID: 27040855.

174 Apice G, Pizzolorusso A, Di Maio M, Grignani G, Gebbia V, Buonadonna A, De Chiara A, Fazioli F, De Palma G, Galizia D, Arcara C, Mozzillo N, Perrone F. Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma. *Sarcoma.* 2016;2016:6862090. doi: 10.1155/2016/6862090. Epub 2016 Feb 25. PubMed PMID: 27019606; PubMed Central PMCID: PMC4785388.

173 Rossi A, Di Maio M. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. *Expert Rev Anticancer Ther.* 2016 Jun;16(6):653-60. doi: 10.1586/14737140.2016.1170596. Epub 2016 Apr 8. PubMed PMID: 27010977.

172 Di Maio M, Bironzo P, Scagliotti GV. Raising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancer. *Transl Lung Cancer Res.* 2016 Feb;5(1):89-91. doi: 10.3978/j.issn.2218-6751.2015.07.18. PubMed PMID: 26958498; PubMed Central PMCID: PMC4758972.

171 Vignani F, Bertaglia V, Buttigliero C, Tucci M, Scagliotti GV, Di Maio M. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. *Cancer Treat Rev.* 2016 Mar;44:61-73. doi: 10.1016/j.ctrv.2016.02.002. Epub 2016 Feb 12. Review. PubMed PMID: 26907461.

170 Di Maio M, Basch E, Bryce J, Perrone F. Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. *Nat Rev Clin Oncol.* 2016 May;13(5):319-25. doi: 10.1038/nrclinonc.2015.222. Epub 2016 Jan 20. Review. PubMed PMID: 26787278.

169 Righi L, Vatrano S, Di Nicolantonio F, Massa F, Rossi G, Cavazza A, Volante M, Votta A, Izzo S, Lo Iacono M, Ardisson F, Di Maio M, Novello S, Scagliotti GV, Papotti M. Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung. *J Thorac Oncol.* 2016 Apr;11(4):504-15. doi: 10.1016/j.jtho.2016.01.004. Epub 2016 Jan 13. PubMed PMID: 26774193.

168 Brizzi MP, Sonetto C, Tampellini M, Di Maio M, Volante M, Scagliotti GV. Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: a case report and review of the literature. *BMC Cancer.* 2015 Nov 18;15:914. doi: 10.1186/s12885-015-1923-4. Review. PubMed PMID: 26582328; PubMed Central PMCID: PMC4652398.

167 Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, Scagliotti GV, Di Maio M. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol.* 2016 Apr;69(4):563-73. doi: 10.1016/j.eururo.2015.09.013. Epub 2015 Sep 28. Review. PubMed PMID: 26422676.

166 Di Maio M, Perrone F. Subgroup Analysis: Refining a Positive Result or Trying to Rescue a Negative One? *J Clin Oncol.* 2015 Dec 20;33(36):4310. doi: 10.1200/JCO.2015.62.6747. Epub 2015 Sep 21. PubMed PMID: 26392099.

165 Cremolini C, Di Maio M, Petrelli F, Berenato R, Loupakis F, Pietrantonio F. BRAF-mutated metastatic colorectal cancer between past and future. *Br J Cancer.* 2015 Dec 1;113(11):1634-5. doi: 10.1038/bjc.2015.316. Epub 2015 Sep 10. PubMed PMID: 26355234; PubMed Central PMCID: PMC4705874.

164 Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M, Scagliotti GV. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. *Cancer Treat Rev.* 2015 Dec;41(10):884-92. doi: 10.1016/j.ctrv.2015.08.002. Epub 2015 Aug 31. Review. PubMed PMID: 26342718.

163 Barni S, Maiello E, Di Maio M, Ardizzoni A, Cappuzzo F, Maranzano E, Novello S, Bennati C, Ori A, Rizzoli S, Crinò L; RIGHT-3 study group. Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study. *Lung Cancer.* 2015 Nov;90(2):234-42. doi: 10.1016/j.lungcan.2015.08.005. Epub 2015 Aug 19. PubMed PMID: 26314614.

162 Scagliotti GV, Di Maio M. Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary

end point was not MET... *Ann Oncol.* 2015 Oct;26(10):2007-9. doi: 10.1093/annonc/mdv334. Epub 2015 Aug 11. PubMed PMID: 26265168.

161 Vincenzi B, Di Maio M, Silletta M, D'Onofrio L, Spoto C, Piccirillo MC, Daniele G, Comito F, Maci E, Bronte G, Russo A, Santini D, Perrone F, Tonini G. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. *PLoS One.* 2015 Jul 31;10(7):e0133488. doi: 10.1371/journal.pone.0133488. eCollection 2015. PubMed PMID: 26230853; PubMed Central PMCID: PMC4521926.

160 Perrone F, Di Maio M, Gallo C. Reply to P. Baldo et al. *J Clin Oncol.* 2015 Sep 1;33(25):2826. doi: 10.1200/JCO.2015.62.5699. Epub 2015 Jul 20. PubMed PMID: 26195706.

159 Courthod G, Tucci M, Di Maio M, Scagliotti GV. Papillary renal cell carcinoma: A review of the current therapeutic landscape. *Crit Rev Oncol Hematol.* 2015 Oct;96(1):100-12. doi: 10.1016/j.critrevonc.2015.05.008. Epub 2015 May 27. Review. PubMed PMID: 26052049.

158 Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, Mosconi AM, Orditura M, Brandes AA, Arcangeli V, Panici PB, Pisano C, Cecere SC, Di Napoli M, Raspagliesi F, Maltese G, Salutari V, Ricci C, Daniele G, Piccirillo MC, Di Maio M, Gallo C, Perrone F; MITO 11 investigators. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. *Lancet Oncol.* 2015 May;16(5):561-8. doi: 10.1016/S1470-2045(15)70115-4. Epub 2015 Apr 14. PubMed PMID: 25882986.

157 Buti S, Bordi P, Tiseo M, Bria E, Sperduti I, Di Maio M, Panni S, Novello S, Rapetti SG, Pilotto S, Genestreti G, Rossi A, Pezzuolo D, Camisa R, Tortora G, Ardizzoni A. Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients. *Lung Cancer.* 2015 Jun;88(3):319-24. doi: 10.1016/j.lungcan.2015.03.016. Epub 2015 Apr 1. PubMed PMID: 25870156.

156 Gridelli C, Balducci L, Ciardiello F, Di Maio M, Felip E, Langer C, Lilienbaum RC, Perrone F, Senan S, de Marinis F. Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. *Clin Lung Cancer.* 2015 Sep;16(5):325-33. doi: 10.1016/j.clc.2015.02.006. Epub 2015 Mar 7. Review. PubMed PMID: 25862554.

155 Di Maio M, Scagliotti GV. The lesson learned from figitumumab clinical program and the hope for better results in squamous lung cancer. *Transl Lung Cancer Res.* 2015 Feb;4(1):15-7. doi: 10.3978/j.issn.2218-6751.2015.01.02. PubMed PMID: 25806342; PubMed Central PMCID: PMC4367709.

154 Di Maio M, Gallo C, Leigh NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. *J Clin Oncol.* 2015 Mar 10;33(8):910-5. doi: 10.1200/JCO.2014.57.9334. Epub 2015 Jan 26. PubMed PMID: 25624439.

153 Rossi A, Di Maio M. LUX-Lung: determining the best EGFR inhibitor in NSCLC? *Lancet Oncol.* 2015 Feb;16(2):118-9. doi: 10.1016/S1470-2045(14)71196-9. Epub 2015 Jan 12. PubMed PMID: 25589190.

152 Galetta D, Cinieri S, Pisconti S, Gebbia V, Morabito A, Borsellino N, Maiello E, Febbraro A, Catino A, Rizzo P, Montrone M, Misino A, Logroscino A, Rizzi D, Di Maio M, Colucci G. Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial. *Clin Lung Cancer.* 2015 Jul;16(4):262-73. doi: 10.1016/j.clc.2014.12.002. Epub 2014 Dec 9. PubMed PMID: 25582493.

151 Perrone F, Nuzzo F, Di Rella F, Gravina A, Iodice G, Labonia V, Landi G, Pacilio C, Rossi E, De Laurentiis M, D'Aiuto M, Botti G, Forestieri V, Lauria R, De Placido S, Tinessa V, Daniele B, Gori S, Colantuoni G, Barni S, Riccardi F, De Maio E, Montanino A, Morabito A, Daniele G, Di Maio M, Piccirillo MC, Signoriello S, Gallo C, de Matteis A. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. *Ann Oncol.* 2015 Apr;26(4):675-82. doi: 10.1093/annonc/mdu564. Epub 2014 Dec 8. PubMed PMID: 25488686.

150 Avallone A, Piccirillo MC, Delrio P, Pecori B, Di Gennaro E, Aloj L, Tatangelo F, D'Angelo V, Granata C, Cavalcanti E, Maurea N, Maiolino P, Bianco F, Montano M, Silvestro L, Terranova

Barberio M, Roca MS, Di Maio M, Marone P, Botti G, Petrillo A, Daniele G, Lastoria S, Iaffaioli VR, Romano G, Caracò C, Muto P, Gallo C, Perrone F, Budillon A. Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial). *BMC Cancer*. 2014 Nov 24;14:875. doi: 10.1186/1471-2407-14-875. PubMed PMID: 25421252; PubMed Central PMCID: PMC4289397.

149 Di Maio M, Perrone F, Deschamps C, Rocco G. A meta-analysis of the impact of bronchial stump coverage on the risk of bronchopleural fistula after pneumonectomy. *Eur J Cardiothorac Surg*. 2015 Aug;48(2):196-200. doi: 10.1093/ejcts/ezu381. Epub 2014 Oct 23. Review. PubMed PMID: 25342849.

148 Rossi A, Chiodini P, Sun JM, O'Brien ME, von Plessen C, Barata F, Park K, Popat S, Bergman B, Parente B, Gallo C, Gridelli C, Perrone F, Di Maio M. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. *Lancet Oncol*. 2014 Oct;15(11):1254-62. doi: 10.1016/S1470-2045(14)70402-4. Epub 2014 Sep 14. Review. PubMed PMID: 25232001.

147 Numico G, Pinto C, Gori S, Ucci G, Di Maio M, Cancian M, De Lorenzo F, Silvestris N. Clinical and organizational issues in the management of surviving breast and colorectal cancer patients: attitudes and feelings of medical oncologists. *PLoS One*. 2014 Jul 1;9(7):e101170. doi: 10.1371/journal.pone.0101170. eCollection 2014. PubMed PMID: 24983237; PubMed Central PMCID: PMC4077745.

146 Passaro A, Di Maio M, Del Signore E, Gori B, de Marinis F. management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis. *Clin Lung Cancer*. 2014 Jul;15(4):307-12. doi: 10.1016/j.clcc.2014.04.006. Epub 2014 May 12. PubMed PMID: 24954231.

145 Daniele G, Di Maio M, Piccirillo MC, Giordano P, Capuano I, Cecere SC, Bryce JC, Pignata S, Perrone F. New biological treatments for gynecological tumors: focus on angiogenesis. *Expert Opin Biol Ther*. 2014 Mar;14(3):337-46. doi: 10.1517/14712598.2014.873401.

144 Normanno N, Rossi A, Morabito A, Signoriello S, Bevilacqua S, Di Maio M, Costanzo R, De Luca A, Montanino A, Gridelli C, Rocco G, Perrone F, Gallo C. Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer. *Lung Cancer*. 2014 May 14. [Epub ahead of print]

143 Pignata S, Di Maio M, Gallo C, Perrone F. Carboplatin plus paclitaxel scheduling for advanced ovarian cancer - Authors' reply. *Lancet Oncol*. 2014 Jun;15(7):e250-1.

142 Di Maio M, De Marinis F, Hirsch FR, Gridelli C. Diagnostic and therapeutic issues for patients with advanced non-small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (Review). *Int J Oncol*. 2014 May 21. [Epub ahead of print]

141 Morabito A, Carillio G, Daniele G, Piccirillo MC, Montanino A, Costanzo R, Sandomenico C, Giordano P, Normanno N, Perrone F, Rocco G, Di Maio M. Treatment of small cell lung cancer. *Crit Rev Oncol Hematol*. 2014 Apr 2. [Epub ahead of print] Review.

140 Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncol*. 2014 Apr;15(4):396-405.

139 De Fiore L, Costantini A, Di Maio M, Gori S, Lorusso D, Rosti G, Pinto C. [Cancer on the big screen. How and when movies deal with oncological diseases]. *Recenti Prog Med*. 2014 May;105(5):198-209. doi: 10.1701/1493.16455. Italian. PubMed PMID: 24873943

138 Cohen MJ, Levy I, Barak O, Bloom AI, Fernández-Ruiz M, Di Maio M, Perrone F, Poon RT, Shouval D, Yau T, Shibolet O. Trans-arterial chemo-embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database. *Liver Int*. 2014 Feb 10. [Epub ahead of print]

137 Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F. Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. *Clin Lung*

Cancer. 2013 Dec 27. [Epub ahead of print] Review.

- 136 Gridelli C, Rossi A, Di Maio M, Leo S, Filipazzi V, Favaretto AG, Burgio MA, Cinieri S, Bianco R, Ciardiello F, Cavanna L, Bordonaro R, Costanzo R, Sandomenico C, Gallo C, Perrone F, Morabito A. Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2014 Mar;15(2):166-70.
- 135 Pilotto S, Di Maio M, Peretti U, Kinspergher S, Brunelli M, Massari F, Sperduti I, Giannarelli D, De Marinis F, Tortora G, Bria E. Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. *Crit Rev Oncol Hematol*. 2013 Dec 1. pii: S1040-8428(13)00252-7. [Epub ahead of print]
- 134 La Verde N, Moretti A, Farina G, Dazzani MC, Gamucci T, Borgonovo K, Botta M, Salesi N, Zuradelli M, Pavese I, Barbieri E, Cretella E, Saladino T, Varese P, Traverso ES, Addamo G, Ciccarese M, Rispoli AI, Pellegrino A, Mentuccia L, Girelli S, Piva S, Di Maio M. Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control. *Future Oncol*. 2013 Dec;9(12):1841-8.
- 133 Di Maio M, Morabito A, Piccirillo MC, Daniele G, Giordano P, Costanzo R, Sandomenico C, Montanino A, Rocco G, Perrone F. Combining anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Better. *Curr Pharm Des*. 2013 Nov 5. [Epub ahead of print]
- 132 Costanzo R, Montanino A, Di Maio M, Piccirillo MC, Sandomenico C, Giordano P, Daniele G, Franco R, Perrone F, Rocco G, Normanno N, Morabito A. Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. *Expert Rev Anticancer Ther*. 2013 Oct;13(10):1207-18.
- 131 Reaume MN, Leighl NB, Mittmann N, Coyle D, Hirsh V, Seymour L, Tu D, Shepherd FA, Graham B, Gridelli C, Perrone F, Di Maio M, Bradbury PA, Evans WK. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial). *Lung Cancer*. 2013 Oct;82(1):115-20.
- 130 Morabito A, Gebbia V, Di Maio M, Cinieri S, Viganò MG, Bianco R, Barbera S, Cavanna L, De Marinis F, Montesarchio V, Costanzo R, Sandomenico C, Montanino A, Mancuso G, Russo P, Nacci A, Giordano P, Daniele G, Piccirillo MC, Rocco G, Gridelli C, Gallo C, Perrone F. Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPP-2 study. *Lung Cancer*. 2013 Jul;81(1):77-83.
- 129 Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Barbato E, Beretta GD, Bravi S, Caffo O, Canobbio L, Carrozza F, Cinieri S, Cruciani G, Dinota A, Gebbia V, Giustini L, Graiff C, Molino A, Muggiano A, Pandoli G, Puglisi F, Tagliaferri P, Tomao S, Lunardi G, Venturini M; AIOM Working Group "Interaction with Regional Sections" (2009-2011). Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM). *Tumori*. 2013 Jan-Feb;99(1):35-8.
- 128 Rocco G, Gatani T, Di Maio M, Meoli I, La Rocca A, Martucci N, La Manna C, Stefanelli F. The impact of decreasing cutoff values for maximal oxygen consumption (VO₂max) in the decision-making process for candidates to lung cancer surgery. *J Thorac Dis*. 2013 Feb;5(1):12-8.
- 127 Di Maio M, Costanzo R, Giordano P, Piccirillo MC, Sandomenico C, Montanino A, Carillio G, Muto P, Jones DR, Daniele G, Perrone F, Rocco G, Morabito A. Integrated Therapeutic Approaches in the Treatment of Locally Advanced Non-small Cell Lung Cancer. *Anticancer Agents Med Chem*. 2013 Jul 1;13(6):844-51.
- 126 Di Maio M, Bria E, Banna GL, Puglisi F, Garassino MC, Lorusso D, Perrone F. Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors. *Anticancer Drugs*. 2013 Feb;24(2):99-111.
- 125 Hotta K, Suzuki E, Di Maio M, Chiodini P, Fujiwara Y, Takigawa N, Ichihara E, Reck M, Manegold C, Pilz L, Hisamoto-Sato A, Tabata M, Tanimoto M, Shepherd FA, Kiura K. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. *Lung Cancer*. 2013 Jan;79(1):20-6.
- 124 Di Maio M, Leighl NB, Gallo C, Feld R, Ciardiello F, Butts C, Maione P, Gebbia V, Morgillo F, Wierzbicki R, Favaretto A, Alam Y, Cinieri S, Siena S, Bianco R, Riccardi F, Spatafora M, Ravaioli A, Felletti R, Fregoni V, Genestreti G, Rossi A, Mancuso G, Fasano M, Morabito A, Tsao MS, Signoriello S, Perrone F, Gridelli C; TORCH Investigators. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. *J Thorac Oncol*. 2012 Dec;7(12):1830-44.

- 123 Rossi A, Martelli O, Di Maio M. Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. *Cancer Treat Rev.* 2013 Aug;39(5):498-506.
- 122 Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, Maione P, Morgillo F, Genestreti G, Favaretto A, Leigh N, Wierzbicki R, Cinieri S, Alam Y, Siena S, Tortora G, Felletti R, Riccardi F, Mancuso G, Rossi A, Cantile F, Tsao MS, Saieg M, da Cunha Santos G, Piccirillo MC, Di Maio M, Morabito A, Perrone F. First-line erlotinib followed by second-line cisplatin gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. *J Clin Oncol.* 2012 Aug 20;30(24):3002-11.
- 121 Signoriello S, Annunziata A, Lama N, Signoriello G, Chiodini P, De Sio I, Daniele B, Di Costanzo GG, Calise F, Olivieri G, Castaldo V, Lanzetta R, Piai G, Marone G, Visconti M, Fusco M, Di Maio M, Perrone F, Gallo C, Gaeta GB. Survival after locoregional treatments for hepatocellular carcinoma: a cohort study in real-world patients. *ScientificWorldJournal.* 2012;2012:564706. doi: 10.1100/2012/564706. Epub 2012 May 3.
- 120 Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, Früh M, Qian W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli O, Lee SM. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. *J Clin Oncol.* 2012 May 10;30(14):1692-8.
- 119 Giuliani F, Di Maio M, Colucci G, Perrone F. Conventional chemotherapy of advanced pancreatic cancer. *Curr Drug Targets.* 2012 Jun;13(6):795-801.
- 118 Di Maio M, Daniele G, Piccirillo MC, Giordano P, Signoriello G, Daniele B, Perrone F. Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials. *Cancers (Basel).* 2012 Jun 5;4(2):549-65. doi: 10.3390/cancers4020549.
- 117 Ciliberto D, Prati U, Roveda L, Barbieri V, Staropoli N, Abbruzzese A, Caraglia M, Di Maio M, Flotta D, Tassone P, Tagliaferri P. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. *Oncol Rep.* 2012 Jun;27(6):1849-56.
- 116 Nuzzo F, Gallo C, Lastoria S, Di Maio M, Piccirillo MC, Gravina A, Landi G, Rossi E, Pacilio C, Labonia V, Di Rella F, Bartiromo A, Buonfanti G, De Feo G, Esposito G, D'Aniello R, Maiolino P, Signoriello S, De Maio E, Tinessa V, Colantuoni G, De Laurentiis M, D'Aiuto M, Di Bonito M, Botti G, Giordano P, Daniele G, Morabito A, Normanno N, de Matteis A, Perrone F. Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBEO study. *Ann Oncol.* 2012 Aug;23(8):2027-33.
- 115 Di Maio M, Krzakowski M, Fougerey R, Kowalski DM, Gridelli C. Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel. *Lung Cancer.* 2012 Jul;77(1):116-20.
- 114 Carillio G, Montanino A, Costanzo R, Sandomenico C, Piccirillo MC, Di Maio M, Daniele G, Giordano P, Bryce J, Normanno N, Rocco G, Perrone F, Morabito A. Cetuximab in non-small-cell lung cancer. *Expert Rev Anticancer Ther.* 2012 Feb;12(2):163-75.
- 113 Di Maio M, Signoriello S, Morabito A, Rossi A, Maione P, Piantedosi F, Bilancia D, Cigolari S, Barbera S, Gebbia V, Daniele B, Robbiati SF, Illiano A, Ceribelli A, Carrozza F, Favaretto A, Piazza E, Piccirillo MC, Daniele G, Giordano P, Costanzo R, Sandomenico C, Rocco G, Gallo C, Perrone F, Gridelli C. Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. *Lung Cancer.* 2012 Jun;76(3):457-64.
- 112 Gridelli C, de Marinis F, Di Maio M, Ardizzoni A, Belani CP, Cappuzzo F, Ciardiello F, Fidias P, Paz-Ares L, Perrone F, Pirker R, De Petris L, Stahel R. Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. *Lung Cancer.* 2012 Jun;76(3):269-79.
- 111 Sandomenico C, Costanzo R, Carillio G, Piccirillo MC, Montanino A, Di Maio M, Rocco G, Normanno N, Perrone F, Morabito A. Bevacizumab in non small cell lung cancer: development, current status and issues. *Curr Med Chem.* 2012;19(7):961-71.
- 110 Gridelli C, Gallo C, Morabito A, Iaffaioli RV, Favaretto A, Isa L, Barbera S, Gamucci T, Ceribelli A, Filipazzi V, Maione P, Rossi A, Barletta E, Signoriello S, De Maio E, Piccirillo MC, Di Maio M, Rocco G, Vecchione A, Perrone F; G-STEP Investigators. Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial. *J Thorac Oncol.* 2012 Jan;7(1):233-42.
- 109 Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Barbato E, Beretta GD, Bravi S, Caffo O, Canobbio L, Carrozza F, Cinieri S, Cruciani G, Dinota A, Gebbia V, Giustini L, Graiff C, Molino A, Muggiano A, Pandoli G, Puglisi F, Tagliaferri P, Tomao S, Venturini M; AIOM Working Group

"Interactions with Regional Sections" (2009-2011). Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM). *Tumori*. 2011 Jul-Aug;97(4):442-8.

108 Marchetti C, Pisano C, Mangili G, Lorusso D, Panici PB, Silvestro G, Candiani M, Greggi S, Perniola G, Di Maio M, Pignata S. Use of adjuvant therapy in patients with FIGO stage III endometrial carcinoma: a multicenter retrospective study. *Oncology*. 2011;81(2):104-12.

107 Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F, Di Maio M, Morabito A, Gallo C, Perrone F. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. *J Clin Oncol*. 2011 Sep 20;29(27):3628-35.

106 Di Maio M. Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer. *Expert Opin Biol Ther*. 2011 Sep;11(9):1131-3.

105 de Bellis M, Accardo R, Di Maio M, La Manna C, Rossi GB, Pace MC, Romano V, Rocco G. Is flexible bronchoscopy necessary to confirm the position of double-lumen tubes before thoracic surgery? *Eur J Cardiothorac Surg*. 2011 Oct;40(4):912-6

104 Costanzo R, Piccirillo MC, Sandomenico C, Carillio G, Montanino A, Daniele G, Giordano P, Bryce J, De Feo G, Di Maio M, Rocco G, Normanno N, Perrone F, Morabito A. Gefitinib in non small cell lung cancer. *J Biomed Biotechnol*. 2011;2011:815269. Epub 2011 May 23.

103 Novello S, Milella M, Tiseo M, Banna G, Cortinovis D, Di Maio M, Garassino M, Maione P, Martelli O, Vavalà T, Bria E. Maintenance therapy in NSCLC: why? To whom? Which agent? *J Exp Clin Cancer Res*. 2011 May 6;30:50.

102 de Marinis F, Rossi A, Di Maio M, Ricciardi S, Gridelli C. Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. *Lung Cancer*. 2011 Jul;73(1):1-10.

101 Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Beretta GD, Caffo O, Caroti C, Crinò L, De Laurentiis M, Dinota A, Di Vito F, Gebbia V, Giustini L, Graiff C, Guida M, Lelli G, Lombardo M, Muggiano A, Puglisi F, Romito S, Salvagno L, Tagliaferri P, Terzoli E, Venturini M; AIOM Working Group Interaction with Regional Sections (2007-2009). Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM). *Tumori*. 2010 Nov-Dec;96(6):1010-5.

100 Daniele G, Giordano P, De Luca A, Piccirillo MC, Di Maio M, Del Giudice A, De Feo G, Bryce J, Lamura L, Vecchione A, Normanno N, Perrone F. Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence. *Expert Rev Anticancer Ther*. 2011 Feb;11(2):299-307.

99 Nuzzo F, Morabito A, Gravina A, Di Rella F, Landi G, Pacilio C, Labonia V, Rossi E, De Maio E, Piccirillo MC, D'Aiuto G, Thomas R, Rinaldo M, Botti G, Di Bonito M, Di Maio M, Gallo C, Perrone F, de Matteis A. Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial. *BMC Cancer*. 2011 Feb 16;11:75.

98 De Vita F, Orditura M, Martinelli E, Vecchione L, Innocenti R, Sileni VC, Pinto C, Di Maio M, Farella A, Troiani T, Morgillo F, Napolitano V, Ancona E, Di Martino N, Ruol A, Galizia G, Del Genio A, Ciardiello F. A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. *Br J Cancer*. 2011 Feb 1;104(3):427-32.

97 Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. *Lung Cancer*. 2011 Apr;72(1):3-8.

96 Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. *Lung Cancer*. 2011 Mar;71(3):249-57.

95 Gridelli C, Morgillo F, Favaretto A, de Marinis F, Chella A, Cerea G, Mattioli R, Tortora G, Rossi A, Fasano M, Pasello G, Ricciardi S, Maione P, Di Maio M, Ciardiello F. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. *Ann Oncol*. 2011 Jul;22(7):1528-34.

| | |
|----|--|
| 94 | Banna GL, Di Maio M, Follador A, Collovà E, Menis J, Novello S, Bria E; on behalf of ISA Co-Authors. Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). <i>Lung Cancer</i> . 2011 Jul;73(1):78-88. Epub 2010 Dec 8. |
| 93 | Di Maio M, Morabito A, Piccirillo MC, Daniele G, Giordano P, Costanzo R, Riccardi MG, Rocco G, Normanno N, Perrone F. New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development. <i>Expert Opin Investig Drugs</i> . 2010 Dec;19(12):1503-14. Epub 2010 Nov 4. |
| 92 | Morabito A, Piccirillo MC, Costanzo R, Sandomenico C, Carillio G, Daniele G, Giordano P, Bryce J, Carotenuto P, La Rocca A, Di Maio M, Normanno N, Rocco G, Perrone F. Vandetanib: An overview of its clinical development in NSCLC and other tumors. <i>Drugs Today (Barc)</i> . 2010 Sep;46(9):683-98. |
| 91 | Fujiwara Y, Hotta K, Di Maio M, Kiura K, Takigawa N, Tabata M, Tanimoto M. Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment. <i>Ann Oncol</i> . 2011 Feb;22(2):376-82. |
| 90 | De Feo G, Signoriello S, Bryce JC, Del Giudice A, Canzanella G, Crudele F, Romano F, de Matteis G, Florio M, Falasconi F, Savio A, Giordano P, Daniele G, Iaccarino M, Piccirillo MC, Di Maio M, Morabito A, Gallo C, Perrone F. Time spent for activation of non-profit studies in oncology in Italy. <i>PLoS One</i> . 2010 Jul 29;5(7):e11864. |
| 89 | Esposito I, de Bellis M, de Leone A, Rossi GB, Selvaggi F, Di Maio M, Musto D, Tracey MC, Marone P, Esposito P, Tempesta A, Riegler G. Endoscopic surveillance for hereditary non-polyposis colorectal cancer (HNPCC) family members in a Southern Italian region. <i>Dig Liver Dis</i> . 2010 Oct;42(10):698-703. |
| 88 | Piccirillo MC, Daniele G, Di Maio M, Bryce J, De Feo G, Del Giudice A, Perrone F, Morabito A. Vinorelbine for non-small cell lung cancer. <i>Expert Opin Drug Saf</i> . 2010 Mar 30. [Epub ahead of print] |
| 87 | Colucci G, La bianca R, Di Costanzo F, Gebbia V, Carteni G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F; Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. <i>J Clin Oncol</i> . 2010 Apr 1;28(10):1645-51. Epub 2010 Mar 1. |
| 86 | Rossi A, Garassino MC, Cinquini M, Sburlati P, Di Maio M, Farina G, Gridelli C, Torri V. Maintenance or consolidation therapy in small-cell lung cancer: A systematic review and meta-analysis. <i>Lung Cancer</i> . 2010 Feb 24. [Epub ahead of print] |
| 85 | Santini V, Alessandrino PE, Angelucci E, Barosi G, Billio A, Di Maio M, Finelli C, Locatelli F, Marchetti M, Morra E, Musto P, Visani G, Tura S. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. <i>Leuk Res</i> . 2010 Feb 11. [Epub ahead of print] |
| 84 | Gridelli C, Di Maio M. The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial. <i>Expert Opin Pharmacother</i> . 2010 Feb;11(2):321-4. |
| 83 | Di Maio M, Lama N, Morabito A, Smit EF, Georgoulas V, Takeda K, Quoix E, Hatzidaki D, Wachters FM, Gebbia V, Tsai CM, Camps C, Schuette W, Chiodini P, Piccirillo MC, Perrone F, Gallo C, Gridelli C. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. <i>Eur J Cancer</i> . 2010 Mar;46(4):735-43. |
| 82 | Gridelli C, Ardizzoni A, Douillard JY, Hanna N, Manegold C, Perrone F, Pirker R, Rosell R, Shepherd FA, De Petris L, Di Maio M, de Marinis F. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Lung Cancer</i> . 2009 Dec 23. |
| 81 | Di Maio M, Gallo C, De Maio E, Morabito A, Piccirillo MC, Gridelli C, Perrone F. Methodological aspects of lung cancer clinical trials in the era of targeted agents. <i>Lung Cancer</i> . 2010 Feb;67(2):127-35. |
| 80 | Di Maio M, Daniele B, Perrone F. Targeted therapies: Role of sorafenib in HCC patients with compromised liver function. <i>Nat Rev Clin Oncol</i> . 2009 Sep;6(9):505-6. |
| 79 | Morabito A, Piccirillo MC, De Maio E, Di Maio M, Perrone F. Trastuzumab beyond progression: is the risk of cardiac toxicity really not increased? <i>J Clin Oncol</i> . 2009 Sep 20;27(27):e123; author reply e124-5. |
| 78 | Bria E, Cuppone F, Di Maio M. Cetuximab for metastatic colorectal cancer. <i>N Engl J Med</i> . 2009 Jul |

2;361(1):95-6; author reply 96-7.

77 Daniele B, Di Maio M. Target therapy for hepatocellular carcinoma: is sorafenib for everybody? *J Clin Gastroenterol.* 2009 May-Jun;43(5):389-90.

76 Di Maio M, Perrone F. Registrative trials of antiemetic drugs: arrival or starting point? *Lancet Oncol.* 2009 Jun;10(6):533-4.

75 Bria E, Di Maio M, Carlini P, Cuppone F, Giannarelli D, Cognetti F, Milella M. Targeting targeted agents: open issues for clinical trial design. *J Exp Clin Cancer Res.* 2009 May 22;28:66.

74 Loupakis F, Di Maio M, Falcone A. Chemotherapy and immunotherapy in metastatic colorectal cancer. *N Engl J Med.* 2009 May 14;360(20):2135; author reply 2135-6.

73 Rossi E, Morabito A, Di Rella F, Esposito G, Gravina A, Labonia V, Landi G, Nuzzo F, Pacilio C, De Maio E, Di Maio M, Piccirillo MC, De Feo G, D'Aiuto G, Botti G, Chiodini P, Gallo C, Perrone F, de Matteis A. Endocrine Effects of Adjuvant Letrozole Compared With Tamoxifen in Hormone-Responsive Postmenopausal Patients With Early Breast Cancer: The HOBEO Trial. *J Clin Oncol.* 2009 Apr 20. [Epub ahead of print]

72 Gridelli C, Morabito A, Gebbia V, Mencoboni M, Carrozza F, Viganò MG, Verusio C, Bollina R, Mattioli R, Valerio MR, Valmadre G, Maione P, Rossi A, Cascone T, Morgillo F, Di Maio M, Piccirillo MC, Gallo C, Perrone F, Ciardiello F. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. *Lung Cancer.* 2009 Apr 18. [Epub ahead of print]

71 Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, Di Maio M, De Maio E, Normanno N, Perrone F. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. *Oncologist.* 2009 Apr;14(4):378-90. Epub 2009 Apr 6.

70 Maione P, Rossi A, Di Maio M, Gridelli C. Tumor-related leucocytosis and chemotherapy-induced neutropenia: Linked or independent prognostic factors for advanced non-small cell lung cancer?. *Lung Cancer.* 2009 Mar 26. [Epub ahead of print]

69 Di Maio M, Chiodini P, Georgoulas V, Hatzidaki D, Takeda K, Wachtors FM, Gebbia V, Smit EF, Morabito A, Gallo C, Perrone F, Gridelli C. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. *J Clin Oncol.* 2009 Apr 10;27(11):1836-43. Epub 2009 Mar 9.

68 Pisano C, Morabito A, Sorio R, Breda E, Lauria R, Gebbia V, Scaltriti L, Scalone S, Zagonel V, Greggi S, Beneduce G, Losito S, Gallo C, Di Maio M, Forestieri V, Pignata S. A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. *Cancer Chemother Pharmacol.* 2009 Mar 6. [Epub ahead of print]

67 Di Maio M, Perrone F. Palonosetron: more than just another option?. *Lancet Oncol.* 2009 Feb;10(2):100-1.

66 Di Maio M, Daniele B, Gallo C, Perrone F. Re: Design and endpoints of clinical trials in hepatocellular carcinoma. *J Natl Cancer Inst* 2008

65 Gridelli C, Ardizzoni A, Ciardiello F, Hanna N, Heymach JV, Perrone F, Rosell R, Shepherd FA, Thatcher N, Vansteenkiste J, De Petris L, Di Maio M, De Marinis F (2008). Second-line treatment of advanced non-small cell lung cancer. *JOURNAL OF THORACIC ONCOLOGY*, vol. 3, p. 430-440.

64 Abruzzese E, Iuliano F, Trawinska MM, Di Maio M. 153Sm: its use in multiple myeloma and report of a clinical experience. *Expert Opin Investig Drugs.* 2008 Sep;17(9):1379-87.

63 Gebbia V, Gridelli C, Verusio C, Frontini L, Aitini E, Daniele B, Gamucci T, Mancuso G, Di Maio M, Gallo C, Perrone F, Morabito A. Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients The DISTAL-2 randomized trial. *Lung Cancer.* 2008 Jul 14. [Epub ahead of print]

62 Di Maio M, Daniele B, Pignata S, Gallo C, De Maio E, Morabito A, Piccirillo MC, Perrone F. Is human hepatocellular carcinoma a hormone-responsive tumor? *World J Gastroenterol.* 2008 Mar 21;14(11):1682-9. Review.

61 Di Maio M, Gallo C, Perrone F. [Meta-analysis of phase III studies with palonosetron in the prevention of vomiting induced by moderately emetogenic chemotherapy] *Tumori.* 2008 Mar-Apr;94(2):suppl 14-22.

60 Gridelli C, Rossi A, Morgillo F, Bareschino MA, Maione P, Di Maio M, Ciardiello F. A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell

lung cancer in elderly patients: treatment rationale and protocol dynamics. *Clin Lung Cancer*. 2007 Nov;8(9):568-71.

59 Di Maio M, Bria E, Rossi A, Perrone F. Progression-free survival as primary end point in advanced non-small-cell lung cancer: does the size matter? *Ann Oncol*. 2008 Feb;19(2):402-3.

58 Daniele B, Annunziata M, Barletta E, Tinessa V, Di Maio M. Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma. *Hepatol Res*. 2007 Sep;37 Suppl 2:S206-9.

57 Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, Carozza F, Favaretto A, Daniele B, Galetta D, Barbera S, Rosetti F, Rossi A, Maione P, Cognetti F, Testa A, Di Maio M, Morabito A, Perrone F; GECO investigators. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEMcitabine-COxib in NSCLC (GECO) study. *Lancet Oncol*. 2007 Jun;8(6):500-12.

56 Pignata S, Scambia G, Pisano C, Breda E, Di Maio M, Greggi S, Ferrandina G, Lorusso D, Zagonel V, Febbraro A, Riva N, De Rosa V, Gallo C, Perrone F; Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies Group. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. *Br J Cancer* 2007; 96(11):1639-43.

55 Pizzi C, Di Maio M, Daniele S, Mastranzo P, Spagnoletti I, Limite G, Pettinato G, Monticelli A, Coccozza S, Contegiacomo A. Triplet repeat instability correlates with dinucleotide instability in primary breast cancer. *Oncol Rep*. 2007 Jan;17(1):193-9.

54 Di Maio M, Perrone F, Chiodini P, Gallo C, Camps C, Schuette W, Quiox E, Tsai CM, Gridelli C. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. *J Clin Oncol* 2007; 25: 1377-1382.

53 Gridelli C, Aapro MS, Barni S, Beretta GD, Colucci G, Daniele B, Del Mastro L, Di Maio M, De Petris L, Perrone F, Thatcher N, De Marinis F. Role of colony stimulating factors in solid tumours: Results of an experts panel. *Crit Rev Oncol Hematol* 2007 Jul;63(1):53-64.

52 Di Maio M, De Maio E, Morabito A, D'Aniello R, De Feo G, Gallo C, Perrone F. Hormonal treatment of human hepatocellular carcinoma. *Ann NY Acad Science* 2006; 1089:252-261

51 Bria E, Di Maio M, Cuppone F, Nisticò C, Cognetti F, Giannarelli D. Should subgroup analysis of randomized clinical trials have a direct impact on clinical practice? (Correspondence) *Journal of Clinical Oncology* 2007; 25: 605-606

50 Picone GM, Pizzi C, Quartuccio A, Scognamiglio G, Tauchmanova L, Di Maio M, Cifarelli P, Contegiacomo A. Incidence and pathological characteristics of prostate cancer in Italy: A contribution to the screening debate. *Cancer Detection and Prevention* 2006; 30: 455-458.

49 Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, Cruciani G, Di Maio M, Andrea B, Deuson RR. The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. *Support Care Cancer*. 2006 Aug 29; [Epub ahead of print]

48 Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F; MITO Investigators. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. *BMC Cancer* 2006; 6: 202.

47 Pacilio C, Morabito A, Nuzzo F, Gravina A, Labonia V, Landi G, Rossi E, De Maio E, Di Maio M, D'Aiuto G, Botti G, Normanno N, Chiodini P, Gallo C, Perrone F, de Matteis A (2006). Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. *BRITISH JOURNAL OF CANCER*, vol. 94, p. 1233-1236, ISSN: 0007-0920, doi: 10.1038/sj.bjc.6603096

46 Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. *Oncologist* 2006; 11: 753-764.

45 Gallo C, De Maio E, Di Maio M, Signoriello G, Daniele B, Pignata S, Annunziata A, Perrone F; CLIP Investigators. Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma. *BMC Cancer* 2006; 6:196

44 Bria E, Di Maio M, Nistico C, Cuppone F, Terzoli E, Cognetti F, Giannarelli D. Factorial design for randomized clinical trials. *Ann Oncol*. 2006; 17: 1607-1608.

43 Pignata S, Pisano C, Di Maio M, Iodice F, Casella G, Laurelli G, Greggi S, Jaffaioli RV. Medical treatment of resistant or recurrent epithelial ovarian cancer. *Ann Oncol*. 2006;17 Suppl 7:vii49-vii50.

| | |
|----|--|
| 42 | Morabito A, Di Maio M, De Maio E, Normanno N, Perrone F. Methodology of clinical trials with new molecular-targeted agents: where do we stand? <i>Ann Oncol</i> 2006;17 Suppl 7: vii128- vii131. |
| 41 | M Di Maio, C Gridelli, C Gallo, F Perrone. Viewpoint: Chemotherapy-induced neutropenia: a useful predictor of treatment efficacy? <i>Nature Clinical Practice Oncology</i> 2006, 3: 2-3 |
| 40 | S Pignata, C Gallo, B Daniele, S Elba, A Giorgio, G Capuano, LE Adinolfi, I De Sio, F Izzo, F Farinati, C Del Naja, M Stanzione, F Castiglione, G Marone, O Cuomo, M Felder, GB Gaeta, E De Maio, M Di Maio, G Signoriello, F Perrone on behalf of the CLIP Investigators. Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP). <i>Crit Rev Oncol Hematol</i> 2006; 59: 243-249 |
| 39 | S Pignata, S De Placido, R Biamonte, G Scambia, G Di Vagno, G Colucci, A Febbraro, A Vernaglia Lombardi, L Manzione, M Nardi, S Danese, MR Valerio, G Gasparini, M Di Maio, C Pisano, F Perrone. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. <i>BMC Cancer</i> 2006; 6:5. |
| 38 | M Di Maio, C Pisano, R Tambaro, S Greggi, G Casella, G Laurelli, R Formato, RV Iaffaioli, F Perrone, S Pignata. The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancer. <i>Frontiers in Bioscience</i> 2006 May 1; 11: 1585-1590. |
| 37 | D Califano, S Losito, C Pisano, G Santelli, S Greggi, F Iodice, G Di Vagno, G Silvestro, R Tambaro, R Formato, RV Iaffaioli, M Di Maio, S Pignata. The significance of erb-B2 immunostaining in cervical cancer <i>Frontiers in Bioscience</i> 2006 September 1; 11: 2071-2076. |
| 36 | M Di Maio, C Gridelli, C Gallo, F Shepherd, FV Piantedosi, S Cigolari, L Manzione, A Illiano, S Barbera, SF Robbiati, L Frontini, E Piazza, GP Ianniello, E Veltri, F Castiglione, F Rosetti, V Gebbia, L Seymour, P Chiodini, F Perrone. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. <i>Lancet Oncology</i> , 2005, Sep;6(9):669-77. |
| 35 | Pisano C, Greggi S, Tambaro R, Losito S, Iodice F, Di Maio M, Ferrari E, Falanga M, Formato R, Iaffaioli VR, Pignata S. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. <i>Anticancer Res.</i> 2005 Sep-Oct;25(5):3501-5. |
| 34 | N Normanno, M Di Maio, E De Maio, A De Luca, A de Matteis, A Giordano, F Perrone on behalf of the NCI- Naples Breast Cancer Group. Invited Review: Mechanisms of endocrine-resistance and novel therapeutic strategies in breast cancer. <i>Endocrine-related Cancer</i> , 2005 Dec;12(4):721-47. |
| 33 | C Gridelli, P Maione, A Rossi, M Di Maio, F Perrone. Chemotherapy of stage I to III non-small-cell lung cancer in elderly patients. 2005 ASCO annual meeting Educational book (supplement of <i>J Clin Oncol</i>), pag.611-617 |
| 32 | C Gridelli, M Aapro, A Ardizzoni, L Balducci, F De Marinis, K Kelly, T Le Chevalier, C Manegold, F Perrone, R Rosell, F Shepherd, L De Petris, M Di Maio, C Langer. Treatment of advanced non-small-cell lung cancer in the elderly: results of an International Expert Panel. <i>Journal of Clinical Oncology</i> 2005, 23(13): 3125-3137 |
| 31 | De Maio E, Gravina A, Pacilio C, Amabile G, Labonia V, Landi G, Nuzzo F, Rossi E, D'Aiuto G, Capasso I, Rinaldo M, Morrica B, Elmo M, Di Maio M, Perrone F, de Matteis A. Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience. <i>BMC Cancer</i> . 2005 Mar 24;5(1):30 |
| 30 | M Di Maio, C Gridelli, N Normanno, F Perrone, F Ciardiello. Trying to compose the puzzle with all the pieces: Epidermal Growth Factor Receptor tyrosine kinase inhibitors in non-small cell lung cancer. <i>J Cell Physiol</i> 2005 Dec;205(3):355-63. |
| 29 | F Perrone, M Di Maio, A Budillon, N Normanno. Targeted therapies and non small cell lung cancer : methodological and conceptual challenge for clinical trials. <i>Curr Opin Oncol</i> 2005 Mar;17(2):123-9. |
| 28 | S Pignata, F Perrone , M Di Maio, C Gallo , S De Placido on behalf of the MITO Investigators. Reply to 136-04 (letter). <i>Journal of Clinical Oncology</i> , 2005 Apr 1;23(10):2436-7 |
| 27 | C Gridelli, C Gallo, M Di Maio, E Barletta, A Illiano, P Maione, S Salvagni, FV Piantedosi, G Palazzolo, O Caffo, A Ceribelli, A Falcone, P Mazzanti, L Brancaccio, MA Capuano, L Isa, S Barbera, F Perrone on behalf of the DISTAL (Docetaxel In Second-line Treatment of Advanced Lung cancer) Investigators. A Randomized clinical trial of two docetaxel regimens (weekly vs 3-week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. <i>British Journal of Cancer</i> 91(12):1996-2004, 2004. |
| 26 | Perrone F, Di Maio M, Gallo C, Gridelli C on behalf of the MILES Investigators, Outcome of PS2 patients in the MILES study. <i>Journal of Clinical Oncology (letter)</i> 2004 Dec 15;22(24):5018-20 |

| | |
|----|--|
| 25 | Tambaro R, Scambia G, Di Maio M, Pisano C, Barletta E, Iaffaioli VR, Pignata S. The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. <i>Crit Rev Oncol Hematol</i> . 2004 Oct;52(1):33-44. |
| 24 | De Luca A, Grassi M, Maiello MR, Di Maio M, Mancino M, De Maio E, Gridelli C, Perrone F, Normanno N. Does the sequence of gemcitabine and vinorelbine affect the efficacy in non-small cell lung cancer? <i>Anticancer Research</i> 24: 2985 – 2990, 2004 |
| 23 | Pisano C, Tambaro R, Di Maio M, Formato R, Iaffaioli VR, Pignata S. Complete resolution of psoriasis in a patient treated with stealth liposomal doxorubicin and carboplatin for ovarian cancer. <i>Arch Dermatol Res</i> . 2004 Aug;296(3):141-2. Epub 2004 Jul 20. |
| 22 | Ottaiano A, Mollo E, Di Lorenzo G, Pisano C, Di Maio M, Barletta E, Pensabene M, Segati R, Bullian P, Nasti G, Bryce J, Scala S, Castello G, Ascierto PA. Prospective clinical trials of biotherapies in solid tumors: a 5-year survey. <i>Cancer Immunol Immunother</i> . 2004 Jul 3 [Epub ahead of print] |
| 21 | M Di Maio, C Gridelli, C Gallo, L Manzione, L Brancaccio, S Barbera, SF Robbiati, GP Ianniello, F Ferrau, E Piazza, L Frontini, F Rosetti, F Carrozza, A Bearz, M Spatafora, V Adamo, L Isa, RV Iaffaioli, E Di Salvo, F Perrone. Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> 2004, 90(12): 2288-2296 |
| 20 | Normanno N, Di Maio M, Perrone F, Campiglio M. Molecular markers to predict response to gefitinib: EGFR, Erb-B2, or more? <i>Journal of Clinical Oncology</i> 2004, 22(10): 2035-36 (letter) |
| 19 | Spagnoletti I, Pizzi C, Gaietta A, Di Maio M, Mastranzo P, Daniele S, Limite G, Pettinato G, Contegiacomo A. Loss of hMSH2 expression in primary breast cancer with p53 alterations. <i>Oncology reports</i> , 11(4): 845-851 |
| 18 | C Gridelli, A Ardizzoni, T LeChevalier, C Manegold, F Perrone, N Thatcher, N van Zandwijk, M Di Maio, O Martelli, F De Marinis. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. <i>Annals of Oncology</i> 15: 419-426, 2004. |
| 17 | M Di Maio, F Perrone, C Gallo, RV Iaffaioli, L Manzione, FV Piantedosi, S Cigolari, A Illiano, S Barbera, SF Robbiati, E Piazza, GP Ianniello, L Frontini, E Veltri, F Castiglione, F Rosetti, E De Maio, P Maione, C Gridelli. Supportive care in patients with advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> 89: 1013-1021, 2003. |
| 16 | M Di Maio, F Perrone. Quality of Life in elderly patients with cancer. <i>Health and Quality of Life Outcomes</i> 1:44, 2003 |
| 15 | R Tambaro, S Greggi, RV Iaffaioli, A Rossi, C Pisano, L Manzione, E Ferrari, M Di Maio, F Iodice, G Casella, G Laurelli, S Pignata. An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer. <i>Annals of Oncology</i> , 14: 1406-1411, 2003 |
| 14 | A Ottaiano, R Tambaro, S Greggi, R Prato, M Di Maio, G Esposito, F Scala, E Barletta, S Losito, R De Vivo, RV Iaffaioli, S Pignata. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma. <i>Anticancer Research</i> , 23: 3465-3468, 2003 |
| 13 | C Gallo, M Di Maio. Quality of life assessment: cancer in the elderly. <i>Tumori</i> 2(1): S61 – S62, 2003. |
| 12 | E. Rossi, F. Perrone, V Labonia, G Landi, F Nuzzo, G Amabile, C Gridelli, M Di Maio, G D’Aiuto, A de Matteis. Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? A single-center phase II study. <i>Oncology</i> , 64: 479-480, 2003. |
| 11 | F.Perrone, M.Di Maio, E. De Maio, P.Maione, A.Ottaiano, M.Pensabene, G.Di Lorenzo, A.Vernaglia Lombardi, G.Signoriello, C.Gallo. Statistical design in phase II clinical trials and their application in breast cancer. <i>Lancet Oncology</i> , 4:305–11, 2002. |
| 10 | Perrone F, M. Di Maio. Elderly cancer patients: our future? <i>Clinica Terapeutica</i> 153(3):159-60, 2002 |
| 9 | C.Pizzi, L.Panico, L.De Marchis, P.Mastranzo, M.Di Maio, C D’Amico, G Limite, G Pettinato, S Coccozza, A R Bianco and A Contegiacomo. P53 expression is decreased in primary breast carcinomas with microsatellite instability. <i>Breast Cancer Research and Treatment</i> 73(3):257-66, 2002. |
| 8 | M. Di Maio, E. De Maio, F. Perrone, S. Pignata and B. Daniele. Hepatocellular carcinoma: systemic treatments. <i>Journal of Clinical Gastroenterology</i> 35(5 suppl 2)- S109- 114, 2002 |
| 7 | C.Gridelli, A.Rossi, E.Barletta, N.Panza, L.Brancaccio, R.Cioffi, T.Pedicini, G.P.Ianniello, E.Piazza, N.Rossi, R.V.Iaffaioli, P.Maione, M. Di Maio, C.Gallo, F.Perrone. Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive small-cell lung cancer: a poorly tolerated regimen. Results of a multicentre phase II study. <i>Lung Cancer</i> ; 36(3):327-32, 2002 |

| | |
|---|--|
| 6 | Pignata S, Di Maio M, Ottaiano A, De Maio E, Barletta E, Pisano C, Tambaro R. Single agents or combination chemotherapy for advanced ovarian carcinoma in elderly patients: pro single agents. <i>Tumori</i> 88(1 Suppl 1):S117-9, 2002. |
| 5 | Ottaiano A, Di Maio M, Tambaro R, Bruni GS, Barletta E, Botti G and Iaffaioli VR. Bladder cancer in a patient with widespread psoriasis treated by topical coal-tar application. <i>BJU International</i> 89 (6cr), 634, 2002 |
| 4 | Perrone F, Gallo C, Daniele B, Gaeta GB, Izzo F, Capuano G, Adinolfi LE, Mazzanti R, Farinati F, Elba S, Piai G, Calandra M, Stanzione M, Mattera D, Aiello A, Sio ID, Castiglione F, Russo M, Persico M, Felder M, Manghisi OG, De Maio E, M Di Maio, Pignata S. Tamoxifen in the Treatment of Hepatocellular Carcinoma: 5-Year Results of the CLIP-1 Multicentre Randomised Controlled Trial. <i>Current Pharmaceutical Design</i> ; 8(11): 1013-19, 2002. |
| 3 | F.Perrone, E.De Maio, P.Maione, M.Di Maio, A.Ottaiano, M.Pensabene, G.Di Lorenzo, A.Vernaglia Lombardi, C.Gallo. Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancer. <i>Journal of Clinical Oncology</i> 20: 52-57, 2002. |
| 2 | Ottaiano A, Barletta E, Maione P, Fiore F, Pisano C, Di Maio M, VR Iaffaioli, C Gridelli. Pancreatic involvement from heavily pretreated small cell lung cancer successfully treated with transcatheter intraarterial chemotherapy. A case report with local and systemic disease control. <i>Tumori</i> 88:535-537, 2002 |
| 1 | C.Gridelli and M.Di Maio. Indication for venous ports in oncology. Comparing different experiences in Europe. <i>Tumori</i> , 87: S69-S70, 2001. |

Torino, 3 dicembre 2016



Il sottoscritto prof. Massimo Di Maio autorizza al trattamento dei propri dati personali, ai sensi del D.Lgs 30-6-2003 n. 196.

